Effect of Fenticonazole Spray in Cutaneous Mycosis: A Double-Blind Clinical Trial versus Cyclopyroxolamine Spray

1990 ◽  
Vol 18 (1) ◽  
pp. 61-67 ◽  
Author(s):  
P. Altmeyer ◽  
S. Nolting ◽  
A. Kuhlwein ◽  
E. Colli ◽  
M. Scatigna
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Clinical Improvement ◽  
Double Blind ◽  
Once Daily ◽  
Treatment Groups ◽  
Double Blind Clinical Trial ◽  
Cutaneous Mycosis ◽  
Drug Free ◽  
Microscopic Findings

A double-blind clinical trial was performed to evaluate efficacy and tolerance of once-daily 2% fenticonazole compared with 1% cyclopyroxolamine spray applied for 2–4 weeks in 100 patients with cutaneous mycotic lesions. After treatment lasting 21.9 ± 6.7 or 22.5 ± 6.2 days, respectively, patients receiving fenticonazole or cyclopyroxolamine had negative microscopic findings and cultures were sterile. Comparable clinical improvement was observed in both treatment groups, with 91.8% and 89.8% of patients, respectively, receiving fenticonazole or cyclopyroxolamine being evaluated as cured or greatly improved. Following a drug-free period, the clinical evaluation of nine (20.9%) patients treated with fenticonazole and 14 (30.4%) treated with cyclopyroxolamine worsened. The incidence of side-effects was low; only one patient withdrew from treatment because of a slight itch. It is suggested that fenticonazole and cyclopyroxolamine are equally effective in eradicating cutaneous mycoses and that their efficacy and tolerance are comparable.

scholarly journals Comparison the Efficacy of Intranasal Ketamine Versus Intravenous Ketorolac on Acute Non-Traumatic Headaches: A Randomized Double-Blind Clinical Trial

2020 ◽  
Author(s):  
Houman Rafiee Sarvari ◽  
Hamidreza Baigrezaii ◽  
Mohammad Nazarianpirdosti ◽  
Amirhossein Meysami ◽  
Roya Safari-Faramani
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Double Blind ◽  
Analgesic Effects ◽  
Headache Severity ◽  
Selective Approach ◽  
Double Blind Clinical Trial ◽  
Group B ◽  
Short Time ◽  
Intravenous Ketorolac

Abstract Introduction: Non - traumatic headaches are one of the most common causes of referral to hospital emergency. This study aimed to compare the efficacy of intranasal ketamine and intravenous ketorolac on acute non-traumatic headaches.Methods: This randomized and double-blind clinical trial in 2019 years. 140 people were randomly divided into intranasal ketamine (A) and intravenous ketorolac (B). Group (A) received ketamine intranasal (0.75 mg/kg, max 75mg), and group B received intravenous ketorolac (30 mg). Headache severity was measured on arrival, 30, 60, and 120 minutes after intervention with Visual Analogue Scale (VAS). The side effects were recorded an hour after the intervention.Result: The mean difference of pain intensity 30, 60, and 120 minutes after the intervention between the two groups were statistically significant (p<0.001). In the first 30 minutes, significant changes were observed in the VAS levels of the two groups. These changes were more and significant in the intranasal ketamine group (p <0.001). Side effects such as fatigue, dizziness, public discomfort, nausea, increased heart rate, and hypertension were significantly higher in the ketamine group (p <0.05).Conclusion: Intranasal ketamine and intravenous ketorolac both effectively reduced headaches. However, more analgesic effects of intranasal ketamine in a short time can be considered as a selective approach to reducing headaches.

scholarly journals Comparison the Efficacy of Intranasal Ketamine Versus Intravenous Ketorolac on Acute Non-traumatic Headaches: A Randomized Double-Blind Clinical Trial

2020 ◽  
Author(s):  
Houman Rafiee Sarvari ◽  
Hamidreza Baigrezaii ◽  
Mohammad Nazarianpirdosti ◽  
Amirhossein Meysami ◽  
Roya Safari-Faramani
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Double Blind ◽  
Analgesic Effects ◽  
Headache Severity ◽  
Selective Approach ◽  
Double Blind Clinical Trial ◽  
Group B ◽  
Short Time ◽  
Intravenous Ketorolac

Abstract Introduction: Non - traumatic headaches are one of the most common causes of referral to hospital emergency. This study aimed to compare the efficacy of intranasal ketamine and intravenous ketorolac on acute non-traumatic headaches.Methods: This randomized and double-blind clinical trial in 2019 years. 140 people were randomly divided into intranasal ketamine (A) and intravenous ketorolac (B). Group (A) received ketamine intranasal (0.75 mg/kg, max 75mg), and group B received intravenous ketorolac (30 mg). Headache severity was measured on arrival, 30, 60, and 120 minutes after intervention with Visual Analogue Scale (VAS). The side effects were recorded an hour after the intervention.Result: The mean difference of pain intensity 30, 60, and 120 minutes after the intervention between the two groups were statistically significant (p<0.001). In the first 30 minutes, significant changes were observed in the VAS levels of the two groups. These changes were more and significant in the intranasal ketamine group (p <0.001). Side effects such as fatigue, dizziness, public discomfort, nausea, increased heart rate, and hypertension were significantly higher in the ketamine group (p <0.05).Conclusion: Intranasal ketamine and intravenous ketorolac both effectively reduced headaches. However, more analgesic effects of intranasal ketamine in a short time can be considered as a selective approach to reducing headaches.Trial registration: IRCT20180108038276N3, Registered 29 September 2019.

A Long Term Double-Blind Clinical Trial of Ibuprofen and Indomethacin in Rheumatoid Arthritis

1975 ◽  
Vol 3 (3) ◽  
pp. 158-171 ◽  
Author(s):  
G L Royer ◽  
T E Moxley ◽  
M S Hearron ◽  
A Miyara ◽  
B M Shenker
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trial ◽  
Side Effects ◽  
Double Blind ◽  
Double Blind Clinical Trial

Two-hundred and eighteen individuals with rheumatoid arthritis were randomly assigned to six months treatment with ibuprofen (900-1800 mg/day) or indomethacin (75-150 mg/day). The drugs were equally effective in the treatment of rheumatoid arthritis while the incidence of indomethacin side-effects was 1·5 times greater than the incidence of ibuprofen side-effects.

Homoeopathic treatment of malaria in Ghana

1996 ◽  
Vol 85 (02) ◽  
pp. 66-70 ◽  
Author(s):  
Veronique M.A. Van Erp ◽  
Martien Brands
Keyword(s):  
Clinical Trial ◽  
Clinical Improvement ◽  
Open Study ◽  
Northern Region ◽  
The Other ◽  
Double Blind ◽  
Double Blind Clinical Trial

AbstractIn a clinic in Tamale (Ghana, Northern Region) patients with malaria were treated with homoeopathic drugs in an open study (n=75), of whom 90.7% (n=68) showed clinical improvement.Subsequently in a randomized, double-blind, clinical trial, one group (n=30) received homoeopathic drugs, of which 83.3% improved clinically, whereas the other group (n=25) received chloroquine with improvement in 72% patients. This difference is not statistically significant due to the limited samples. The results do, however, suggest further research with larger groups.

scholarly journals Rhodomyrtone as a New Natural Antibiotic Isolated from Rhodomyrtus tomentosa Leaf Extract: A Clinical Application in the Management of Acne Vulgaris

Antibiotics ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 108
Author(s):  
Suttiwan Wunnoo ◽  
Siwaporn Bilhman ◽  
Thanaporn Amnuaikit ◽  
Julalak C. Ontong ◽  
Sudarshan Singh ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Clinical Assessment ◽  
Leaf Extract ◽  
Acne Vulgaris ◽  
Treated Group ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Treatment Groups ◽  
Rhodomyrtus Tomentosa

Rhodomyrtone, a plant-derived principal compound isolated from Rhodomyrtus tomentosa (Myrtaceae) leaf extract, was assessed as a potential natural alternative for the treatment of acne vulgaris. The clinical efficacy of a 1% liposomal encapsulated rhodomyrtone serum was compared with a marketed 1% clindamycin gel. In a randomized and double-blind controlled clinical trial, 60 volunteers with mild to moderate acne severity were assigned to two groups: rhodomyrtone serum and clindamycin gel. The volunteers were instructed to apply the samples to acne lesions on their faces twice daily. A significant reduction in the total numbers of acne lesions was demonstrated in both treatment groups between week 2 and 8 (p < 0.05). Significant differences in acne numbers compared with the baseline were evidenced at week 2 onwards (p < 0.05). At the end of the clinical trial, the total inflamed acne counts in the 1% rhodomyrtone serum group were significantly reduced by 36.36%, comparable to 34.70% in the clindamycin-treated group (p < 0.05). Furthermore, a commercial prototype was developed, and a clinical assessment of 45 volunteers was performed. After application of the commercial prototype for 1 week, 68.89% and 28.89% of volunteers demonstrated complete and improved inflammatory acne, respectively. All of the subjects presented no signs of irritation or side effects during the treatment. Most of the volunteers (71.11%) indicated that they were very satisfied. Rhodomyrtone serum was demonstrated to be effective and safe for the treatment of inflammatory acne lesions.

scholarly journals Treatment of patients with Schistosomiasis mansoni: a double blind clinical trial comparing praziquantel with oxamniquine

1986 ◽  
Vol 28 (3) ◽  
pp. 174-180 ◽  
Author(s):  
Luiz Caetano da Silva ◽  
José Murilo R. Zeitune ◽  
Lucia Maria F. Rosa-Eid ◽  
Dirce Mary C. Lima ◽  
Rita H. Antonelli ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Statistical Significance ◽  
Double Blind ◽  
Chemical Structures ◽  
Double Blind Clinical Trial ◽  
Negative Findings ◽  
Rectal Biopsies ◽  
Cure Rates

A double-blind clinical trial involving 120 patients with chronic schistosomiasis was carried out to compare the tolerability and efficacy of praziquantel and oxamniquine. The patients were randomly allocated into two groups. One was treated with praziquantel, 55 mg/kg of body weight CBWT), and the other one with oxamniquine, 15mg/kg bwt, administered in a single oral dose. The diagnosis and the parasitological follow-up was based on stool examinations by quantitative Kato-Katz method and on rectal biopsies. Side-effects — mainly dizziness, sleepness, abdominal distress, headache, nausea and diarrhea — were observed in 87% of the cases. Their incidence, intensity and duration were similar for both drugs but abdominal pain was significantly more frequent after praziquantel intake and severe dizziness was more commonly reported after oxamniquine. A significant increase of alanine-aminotransferase and y-glutamyltransferase was found with the latter drug and of total bilirubin with the former one. A total of 48 patients treated with praziquantel and 46 with oxamniquine completed with negative findings the required three post-treatment parasitological controls — three slides of each stool sample on the first, third and sixth month. The achieved cure rates were 79.2% and 84.8%, respectively, a difference without statistical significance. The non-cured cases showed a mean reduction in the number of eggs per gram of feces of 93.5% after praziquantel and of 84.1% after oxamniquine. This diference also was not significant. Five patients retreated with praziquantel were cured but only one out of three treated a second time with oxamniquine. These findings show that both drugs — despite their different chemical structures, pharmacological properties and mechanisms-of-action — induce similar side-effects as well as a comparable therapeutical efficacy, in agreement with the results reported from analogous investigations.

Sign in / Sign up

Export Citation Format

Share Document